| Autor: |
Ismail, Tarek I., Bader, Mohamed, Mahrous, Rabab S. S., Abulfatth, Amr M. |
| Předmět: |
|
| Zdroj: |
Research & Opinion in Anesthesia & Intensive Care; Apr-Jun2024, Vol. 11 Issue 2, p92-101, 10p |
| Abstrakt: |
Background: Since the declaration of coronavirus disease 2019 (COVID-19) as a pandemic by the WHO in January 2020, efforts have been exerted by the scientific community to clarify the pathogenesis of severe acute respiratory syndrome-related coronavirusinduced acute lung injury. Corticosteroids, inhaled vasodilators, B2 agonists, surfactant therapy, antibiotics, and/or antiviral agents are used as a pharmacological treatment for acute respiratory distress syndrome. However, we studied whether prophylactic nebulized heparin could limit this form of lung injury. Patients and methods: In all, 100 adult patients with COVID-19 suffering from moderate symptoms of the disease were randomized to prophylactic nebulized heparin (1000 IU/kg) every 6 h or placebo. The primary outcome of this study was the average daily ratio of partial pressure of PaO2 to FiO2 (P/F ratio), while the patient was on room air for 7 days. The secondary outcome was the levels of fibrin degradation products in the pulmonary lavage fluid measured at baseline and on study days 3 and 7 through minibronchoalveolar lavage (mini-BAL) fluid samples. Results: We found nebulized heparin was accompanied by a better hypoxic index as it was linked to a lesser D-dimer change at the intermediate phase of the study (day 3). Moreover, nebulized heparin was not associated with bleeding complications. Conclusion: In conclusion, prophylactic nebulized heparin may provide an adequate therapeutic approach in COVID-19 patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
